Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2005-01-31
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Establish a clinical database and a DNA bank for 1000 individuals with AF and 1000 individuals without AF.
2. Directly test the hypothesis that known functional polymorphisms in the coding sequences and the promoter regions of cardiac genes (ion channels and genes known to affect survival in the setting of left ventricular dysfunction) predispose individuals to AF.
Over the past decade, advancing techniques and technologies for gene characterization have yielded significant clues as to the molecular mechanism of certain human heart rhythm disorders. The role of ion channel polymorphisms in subjects with AF is unknown. Similarly, it is also not known whether polymorphisms in other genes have an impact on the risk of AF.
The ability to characterize genomic "at-risk" profiles would have many potential benefits for patient care. Paramount among these is:
1. Increased oversight or intervention of at-risk subjects, which might prevent unnecessary morbidity and mortality due to AF.
2. Further insight into the pathogenesis of AF, which may lead to preventative or curative therapies.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation
NCT00599118
The Genetic Basis for Atrial Fibrillation
NCT03491202
Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation
NCT05190679
Identification of Genetic Markers for Cardiopulmonary Diseases (Genotype)
NCT00616369
Gene Expression Profiling in Subjects With Postoperative Atrial Fibrillation After Cardiac Surgery (GENEXPRO Surg)
NCT00833313
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Our goal with this research is to:
1. Establish a clinical database and a DNA bank for 1000 individuals with AF and 1000 individuals without AF.
2. Directly test the hypothesis that known functional polymorphisms in the coding sequences and the promoter regions of cardiac genes (ion channels and genes known to affect survival in the setting of left ventricular dysfunction) predispose individuals to AF.
Over the past decade, advancing techniques and technologies for gene characterization have yielded significant clues as to the molecular mechanism of certain human heart rhythm disorders. The role of ion channel polymorphisms in subjects with AF is unknown. Similarly, it is also not known whether polymorphisms in other genes have an impact on the risk of AF.
The ability to characterize genomic "at-risk" profiles would have many potential benefits for patient care. Paramount among these is:
1. Increased oversight or intervention of at-risk subjects, which might prevent unnecessary morbidity and mortality due to AF.
2. Further insight into the pathogenesis of AF, which may lead to preventative or curative therapies.
Subjects will be recruited from the patient pool of the Cardiovascular Institute (including the Comprehensive Heart Center and the PUH Outpatient Cardiology Clinic). For each subject enrolled, we will record demographic information; etiology and details of heart disease; family history of heart disease; non-cardiac medical history; physical exam findings; medicinal therapy; and results of prior cardiac testing (such as echocardiograms \[Echo\], gated blood pool scans of heart function \[MUGAs\], exercise stress tests \[ESTs\] cardiac catheterizations, and clinical electrophysiology studies \[EP Studies\]. Records will be maintained with identifiers in a locked file cabinet in the office of the Principal Investigator.
A blood sample of \~10 ml will be drawn from each participating subject on the day of enrollment. Blood samples will be drawn only once from each subject. There is no further follow up required for the subject. Blood will be sent to the University of Pittsburgh School of Medicine Cardiovascular Research Center where nucleated cells will be isolated from whole blood by centrifugation. DNA will be isolated from nucleated cells and stored at the Cardiovascular Research Center (on the 17th floor of the Biomedical Science Tower). All DNA samples will be coded to ensure confidentiality, and maintained in a locked freezer for the duration of the study (5 years). Samples will be destroyed if requested by the subject. Samples (blood and DNA) will be under the control of the Principal Investigator. The DNA samples will be used to identify polymorphisms in ion channel genes, as well as other genes that may be associated with an increased risk of AF. Genotyping of polymorphisms will be performed on the genomic DNA. The genomic DNA will be amplified by polymerase chain reaction method using gene-specific primers. For each polymorphism, genotype will be identified. We will determine the frequency of that genotype in our study population, and attempt to define significant associations with AF.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Patients of the Cardiovascular Institute with known cardiac conditions and no history of atrial fibrillation.
No interventions assigned to this group
2
Patients of the Cardiovascular Institute with known cardiac conditions and a history of atrial fibrillation.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to give informed consent
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
EP Research funds
UNKNOWN
University of Pittsburgh
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David S. Schwartzman, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pittsburgh/UPMC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Pittsburgh Medical Center/Comprehensive Heart Ctr.
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gensini F, Padeletti L, Fatini C, Sticchi E, Gensini GF, Michelucci A. Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol. 2003 Jan;26(1P2):295-8. doi: 10.1046/j.1460-9592.2003.00036.x.
Lai LP, Lin JL, Lin CS, Yeh HM, Tsay YG, Lee CF, Lee HH, Chang ZF, Hwang JJ, Su MJ, Tseng YZ, Huang SK. Functional genomic study on atrial fibrillation using cDNA microarray and two-dimensional protein electrophoresis techniques and identification of the myosin regulatory light chain isoform reprogramming in atrial fibrillation. J Cardiovasc Electrophysiol. 2004 Feb;15(2):214-23. doi: 10.1046/j.1540-8167.2004.03423.x.
Gaudino M, Andreotti F, Zamparelli R, Di Castelnuovo A, Nasso G, Burzotta F, Iacoviello L, Donati MB, Schiavello R, Maseri A, Possati G. The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation. 2003 Sep 9;108 Suppl 1:II195-9. doi: 10.1161/01.cir.0000087441.48566.0d.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0405107
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.